12.02.2018
- Janssen Biotech, part of pharma and consumer goods giant Johnson & Johnson, has entered into a global development and commercialization agreement with Theravance Biopharma Ireland...
19.06.2013
- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week...
18.06.2013
- Elan shareholders approved a share buyback on Monday, meaning U.S.-based Royalty Pharma's hostile bid for the Irish drug firm will lapse unless it succeeds in a legal challenge...
07.06.2013
- Royalty Pharma received a blow in its battle to take over Irish drug firm Elan on Thursday after a ruling on conditions attached to the U.S. company's hostile bid threatened to...
13.05.2013
- Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21% of the royalties that U.S. company Theravance receives from GlaxoSmithKline for...
